Fatal Chronic Active Epstein-Barr Virus Infection in a Rheumatoid Arthritis Patient Treated with Abatacept

Akio Kawabe; Kazuhisa Nakano; Hiroko Miyata; Ryo Shibuya; Atsuji Matsuyama; Takaaki Ogoshi; Yoshiya Tanaka

doi:10.2169/internalmedicine.1280-18

CASE REPORTS

Fatal Chronic Active Epstein-Barr Virus Infection in a Rheumatoid Arthritis Patient Treated with Abatacept

Akio Kawabe, Kazuhisa Nakano, Hiroko Miyata, Ryo Shibuya, Atsuji Matsuyama, Takaaki Ogoshi, Yoshiya Tanaka

著者情報

Akio Kawabe
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
Kazuhisa Nakano
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
Hiroko Miyata
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
Ryo Shibuya
The Department of Pathology and Oncology, School of Medicine, University of Occupational and Environmental Health, Japan
Atsuji Matsuyama
The Department of Pathology and Oncology, School of Medicine, University of Occupational and Environmental Health, Japan
Takaaki Ogoshi
The Department of Respiratory Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
Yoshiya Tanaka
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan

キーワード: chronic active Epstein-Barr virus infection, rheumatoid arthritis, abatacept

ジャーナルオープンアクセス

2019 年 58 巻 4 号 p. 585-591

DOI https://doi.org/10.2169/internalmedicine.1280-18

Browse “Advance online publication” version

詳細

抄録

Chronic active Epstein-Barr virus (CAEBV) T-cell type infection, systemic form, is characterized by persistent infectious mononucleosis-like symptoms, high Epstein-Barr virus (EBV) DNA levels in the peripheral blood, organ damage, and a poor prognosis. The association between CAEBV and rheumatoid arthritis (RA) is unclear. We report a case of fatal CAEBV T-cell type infection in an RA patient undergoing treatment with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin fusion protein (abatacept, ABT). CAEBV can rapidly worsen in RA patients receiving ABT. Thus, we should try to establish an early diagnosis in patients with CAEBV infection.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）